* Procept Biorobotics Corp PRCT.OQ reported a quarterly
adjusted
loss of 40 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -51 cents. The mean expectation of
seven analysts for the quarter was for a loss of 49 cents per
share. Wall Street expected results to range from -51 cents
to -44 cents per share.
* Revenue rose 66.3% to $58.37 million from a year ago;
analysts
expected $53.18 million.
* Procept Biorobotics Corp's reported EPS for the quarter
was a
loss of 40 cents.
* The company reported a quarterly loss of $20.97 million.
* Procept Biorobotics Corp shares had fallen by 14.2% this
quarter and gained 64.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 0.2%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for Procept
Biorobotics Corp is 94.50
This summary was machine generated from LSEG data October 28 at
07:53 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.49 -0.40 Beat
Jun. 30 2024 -0.52 -0.50 Beat
Mar. 31 2024 -0.56 -0.51 Beat
Dec. 31 2023 -0.44 -0.54 Missed